CTLA4 and melanoma: We found that group 2 patients have significantly higher CYT, MHC, and immune scores than group 1 (Fig. 6d, two-sided Wilcoxon-Mann-Whitney test, all p < 9.46e-12) Treatment with immune checkpoint blockade has transformed the outcome for patients with melanoma, such as programmed cell death protein 1 (PDCD1) inhibitors, CTLA4 inhibitor43.